文献速递妇科母胎医学

NBN致病性变异与卵巢癌风险的系统综述与荟萃分析

Risk of ovarian cancer in women with a pathogenic or likely pathogenic variant in NBN: a systematic review and meta-analysis.
PubMed 文献 · Am J Obstet Gynecol · 2026-02-16

该系统综述与荟萃分析纳入57项研究(n=40,537),评估携带NBN致病性变异女性卵巢癌风险。在白人队列中,NBN致病性变异与卵巢癌风险升高相关(OR 1.68,95%CI 1.37-2.07,P<.001),c.657_661del变异风险更高(OR 2.69,95%CI 1.58-4.57,P<.001)。非白人队列及家族史数据不足。

要点

  • 白人女性NBN致病性变异卵巢癌风险OR为1.68(95%CI 1.37-2.07)。
  • c.657_661del变异卵巢癌风险OR为2.69(95%CI 1.58-4.57)。
  • 非高级别浆液性癌风险关联强于高级别浆液性癌。

核心结论

  • 在白人人群中,NBN致病性变异与卵巢癌存在明确关联。
  • 该关联在非高级别浆液性癌中可能强于高级别浆液性癌。
  • 非白人人群及有家族史者的数据不足,需进一步研究确认。

研究设计与样本

  • 系统综述与荟萃分析,遵循PRISMA指南并注册于PROSPERO(CRD42024567791)。
  • 检索PubMed和Embase自建库至2026年1月,最终纳入57项研究(n=40,537)。
  • 其中36项研究为白人为主队列(n=33,822),21项为非白人队列(n=6,715)。

主要发现

  • 白人队列中,NBN致病性变异卵巢癌OR为1.68(95%CI 1.37-2.07,P<.001)。
  • 白人队列中,衍生相对风险为1.66%,终生风险为3.32%。
  • c.657_661del变异OR为2.69(95%CI 1.58-4.57,P<.001),相对风险2.60%,终生风险5.2%。
  • 高级别浆液性癌OR为1.58(95%CI 1.02-2.45,P=.039),非高级别浆液性癌OR为2.43(95%CI 1.56-3.81,P<.001)。
  • 非白人队列及有卵巢癌家族史病例的数据不足以进行有意义推断。

关键数值与推荐

  • 白人队列NBN致病性变异卵巢癌OR 1.68(95%CI 1.37-2.07)。
  • c.657_661del变异OR 2.69(95%CI 1.58-4.57)。
  • 高级别浆液性癌OR 1.58(95%CI 1.02-2.45),非高级别浆液性癌OR 2.43(95%CI 1.56-3.81)。
  • 白人队列终生风险3.32%,c.657_661del变异终生风险5.2%。

临床怎么用

  • 对白人女性NBN致病性变异携带者可考虑纳入卵巢癌风险预测模型。
  • 未来可结合多基因风险评分等风险因素识别高风险NBN阳性女性以提供手术预防。
  • 非白人人群及有家族史者的风险数据不足,临床决策需谨慎。

局限性

  • 非白人队列数据不足,无法得出有意义的关联结论。
  • 有卵巢癌家族史病例的数据不足,无法确认家族史与风险的关联。
  • 研究以白人为主,结果外推至其他人群受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: NBN is a putative ovarian cancer susceptibility gene. The association between a pathogenic variant in NBN and ovarian cancer is not well established. We aimed to estimate the ovarian cancer risk in unselected women with an NBN pathogenic variant. DATA SOURCES: PubMed and Embase searched from inception to January 2026. ELIGIBILITY CRITERIA: Population: Women diagnosed with ovarian cancer undergoing germline sequencing of NBN (intervention). STUDY APPRAISAL AND SYNTHESIS METHODS: We followed a prospective protocol as per Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (International Prospective Register of Systematic Reviews [PROSPERO]: CRD42024567791). The number of NBN pathogenic variants in ovarian cancer cases in included studies was pooled and an estimated odds calculated. This was compared to the odds of an NBN loss-of-function variant in Genome Aggregation Database v4.1 controls of matched ethnicities to obtain the odds ratio of ovarian cancer with an NBN pathogenic variant. We performed prespecified subgroup analyses for high-grade serous carcinoma and non-high-grade serous carcinoma, and those with a family history of ovarian cancer. RESULTS: Searches yielded 9025 studies; 57 studies (n=40,537) were included in our initial analysis: 36 in majority White cohorts (n=33,822) and 21 in non-White cohorts (n=6715). In the White cohorts, the odds ratio of ovarian cancer with an NBN pathogenic variant was 1.68 (95% confidence interval, 1.37-2.07; P<.001), and the derived relative risk and lifetime risk of ovarian cancer 1.66% and 3.32%, respectively. For the most common pathogenic variant c.657_661del, the odds ratio was 2.69 (95% confidence interval, 1.58-4.57; P<.001), and the relative risk and lifetime risk of ovarian cancer 2.60% and 5.2%, respectively. The odds ratio of high-grade serous carcinoma and non-high-grade serous carcinoma is 1.58 (95% confidence interval, 1.02-2.45; P=.039) and 2.43 (95% confidence interval, 1.56-3.81; P<.001), respectively. Data in non-White cohorts and in ovarian cancer cases with family history were insufficient for any meaningful inference. CONCLUSION: There is a clear association between an NBN pathogenic variant and ovarian cancer in the White population, and this may be stronger with non-high-grade serous carcinoma compared to high-grade serous carcinoma. Further data are required to confirm the association with family history or establish any association in the non-White population. NBN pathogenic variants could be combined with other nongenetic and genetic (polygenic risk score) ovarian cancer risk factors using complex ovarian cancer risk-prediction models going forward, to identify several NBN-positive women at an ovarian cancer risk level for offering surgical prevention.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Ganesan S, Mansour L, Dibden A, et al. Risk of ovarian cancer in women with a pathogenic or likely pathogenic variant in NBN: a systematic review and meta-analysis. Am J Obstet Gynecol. 2026. PMID: 41707894. doi:10.1016/j.ajog.2026.02.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。